Ting Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ting Wang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Wenlin Yang
Department of Pathology, Nantong Tumor Hospital Affiliated to Nantong University, Nantong, 226006, Jiangsu, People's Republic of China
2 shared publications- Chuanbing Hu
Department of Pediatric Surgery, Affiliated Hospital of Jining Medical University, Jining City, China
1 shared publication Chunyu Bai
Precision Medicine Laboratory for Chronic Non-communicable Diseases of Shandong Province, Institute of Precision Medicine, Jining Medical University, Jining, Shandong, 272067, PR China
1 shared publicationDongchang Yang
Department of Surgery, Affiliated Hospital of Jining Medical University, Jining Medical University
1 shared publication- Fang Ruan
Department of Obstetrics, Affiliated Hospital of Jining Medical University, Jining, Shandong Province, 272029, PR China
1 shared publication Junjun Zhang
Department of Pathology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, China
1 shared publication
Latest Publications
- 19 June 2026
- Published by Springer Nature in Head and Neck Pathology
- Vol. 20 (1)
DEK::AFF2 Fusion-Associated Nonkeratinizing Squamous Cell Carcinoma with Noncontiguous Middle Ear and Sinonasal Involvement
DEK::AFF2 fusion-associated nonkeratinizing squamous cell carcinoma is a recently recognized HPV-independent entity characterized by deceptively bland morphology and potential mimicry of benign or inflammatory lesions. A 21-year-old woman presented with recurrent left-sided otorrhea and progressive hearing loss. Imaging demonstrated noncontiguous lesions involving the left middle ear/mastoid compartment and the sinonasal region. Histologically, both lesions showed nonkeratinizing squamous proliferation with focal papillary/inverted architecture, mild to moderate cytologic atypia, and focal stromal invasion. Immunohistochemically, the tumor exhibited diffuse nuclear AFF2 expression, positivity for CK5/6 and p40, wild-type p53 expression, and negative p16 and INSM1. Targeted next-generation sequencing confirmed DEK::AFF2 fusion in both lesions. This case expands the anatomic spectrum of DEK::AFF2 fusion-associated nonkeratinizing squamous cell carcinoma by demonstrating noncontiguous middle ear and sinonasal involvement. Recognition of its characteristic morphologic, immunophenotypic, and molecular features is essential to avoid misdiagnosis.
- 19 June 2026
- Published by Springer Nature in Head and Neck Pathology
- Vol. 20 (1)
DEK::AFF2 Fusion-Associated Nonkeratinizing Squamous Cell Carcinoma with Noncontiguous Middle Ear and Sinonasal Involvement
DEK::AFF2 fusion-associated nonkeratinizing squamous cell carcinoma is a recently recognized HPV-independent entity characterized by deceptively bland morphology and potential mimicry of benign or inflammatory lesions. A 21-year-old woman presented with recurrent left-sided otorrhea and progressive hearing loss. Imaging demonstrated noncontiguous lesions involving the left middle ear/mastoid compartment and the sinonasal region. Histologically, both lesions showed nonkeratinizing squamous proliferation with focal papillary/inverted architecture, mild to moderate cytologic atypia, and focal stromal invasion. Immunohistochemically, the tumor exhibited diffuse nuclear AFF2 expression, positivity for CK5/6 and p40, wild-type p53 expression, and negative p16 and INSM1. Targeted next-generation sequencing confirmed DEK::AFF2 fusion in both lesions. This case expands the anatomic spectrum of DEK::AFF2 fusion-associated nonkeratinizing squamous cell carcinoma by demonstrating noncontiguous middle ear and sinonasal involvement. Recognition of its characteristic morphologic, immunophenotypic, and molecular features is essential to avoid misdiagnosis.
- Open Access
- 12 September 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 972650
Case report: ZEB1 expression in three cases of hepatic carcinosarcoma
Hepatic carcinosarcoma (HCS) is defined as a tumor that contains cancer from the epithelium and sarcoma from mesenchymal tissue. HCS has a low incidence rate and is composed of osteosarcoma, chondrosarcoma, or angiosarcoma. Though surgery is the main treatment for HCS, it has proven unsatisfactory, resulting in a very poor prognosis of HCS. Currently, the reports on HCS are mainly about the description of clinical pathological phenomena, imaging features, and mutation sites of related genes, the underlying molecular mechanism of HCS remains undefined. Through the dynamic process of epithelial-mesenchymal transition (EMT), cancer cells acquire a mesenchymal phenotype, simultaneously losing epithelial properties. Zinc finger E-box binding homeobox 1 (ZEB1) is an EMT-inducing transcription factor; its main regulatory target is E-cadherin in EMT process. Esophageal carcinosarcoma (ECS) is associated with EMT. The current study showed that EMT might promote the development of ECS and uterine carcinosarcoma (UCS), and ZEB1 was highly expressed in the sarcomatous components. In the current study, three cases were collected, and the clinicopathological features were compared with those of corresponding cases. The expression level, and subcellular localization of ZEB1 were detected using immunohistochemistry. The expression of the ZEB1 in the nucleus was found to be significantly higher in sarcomatous components than that in cancer components in all three cases, suggesting an association of HCS with EMT.
- 12 September 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 972650
Open AccessCase report: ZEB1 expression in three cases of hepatic carcinosarcoma
Hepatic carcinosarcoma (HCS) is defined as a tumor that contains cancer from the epithelium and sarcoma from mesenchymal tissue. HCS has a low incidence rate and is composed of osteosarcoma, chondrosarcoma, or angiosarcoma. Though surgery is the main treatment for HCS, it has proven unsatisfactory, resulting in a very poor prognosis of HCS. Currently, the reports on HCS are mainly about the description of clinical pathological phenomena, imaging features, and mutation sites of related genes, the underlying molecular mechanism of HCS remains undefined. Through the dynamic process of epithelial-mesenchymal transition (EMT), cancer cells acquire a mesenchymal phenotype, simultaneously losing epithelial properties. Zinc finger E-box binding homeobox 1 (ZEB1) is an EMT-inducing transcription factor; its main regulatory target is E-cadherin in EMT process. Esophageal carcinosarcoma (ECS) is associated with EMT. The current study showed that EMT might promote the development of ECS and uterine carcinosarcoma (UCS), and ZEB1 was highly expressed in the sarcomatous components. In the current study, three cases were collected, and the clinicopathological features were compared with those of corresponding cases. The expression level, and subcellular localization of ZEB1 were detected using immunohistochemistry. The expression of the ZEB1 in the nucleus was found to be significantly higher in sarcomatous components than that in cancer components in all three cases, suggesting an association of HCS with EMT.
- Open Access
- 31 March 2022
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 13, 878658
Correlation Between Immune Cell Infiltration and PD-L1 Expression and Immune-Related lncRNA Determination in Triple-Negative Breast Cancer
As a key element of the tumor microenvironment (TME), immune cell infiltration (ICI) is a frequently observed histologic finding in people with triple-negative breast cancer (TNBC), and it is linked to immunotherapy sensitivity. Nonetheless, the ICI in TNBC, to the best of our knowledge, has not been comprehensively characterized. In our current work, computational algorithms based on biological data from next-generation sequencing were employed to characterize ICI in a large cohort of TNBC patients. We defined various ICI patterns by unsupervised clustering and constructed the ICI scores using the principal component analysis (PCA). We observed patients with different clustering patterns had distinct ICI profiles and different signatures of differentially expressed genes. Patients with a high ICI score tended to have an increased PD-L1 expression and improved outcomes, and these patients were associated with decreased tumor mutational burden (TMB). Interestingly, it was showed that patients with high TMB exhibited an ameliorated overall survival (OS) than patients with low TMB. Furthermore, TMB scores only affected the prognosis of TNBC patients in the low-ICI score group but not in the high group. Finally, we identified a new immune-related lncRNA (irlncRNA) signature and established a risk model for the TNBC prognosis prediction. In addition, the high-risk group was related to poor prognosis, a high infiltration level of plasma B cells, monocytes, M2 macrophages, and neutrophils and a low PD-L1 expression. Therefore, the characterization and systematic evaluation of ICI patterns might potentially predict the prognosis and immunotherapy response in TNBC patients.
- 31 March 2022
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 13, 878658
Open AccessCorrelation Between Immune Cell Infiltration and PD-L1 Expression and Immune-Related lncRNA Determination in Triple-Negative Breast Cancer
As a key element of the tumor microenvironment (TME), immune cell infiltration (ICI) is a frequently observed histologic finding in people with triple-negative breast cancer (TNBC), and it is linked to immunotherapy sensitivity. Nonetheless, the ICI in TNBC, to the best of our knowledge, has not been comprehensively characterized. In our current work, computational algorithms based on biological data from next-generation sequencing were employed to characterize ICI in a large cohort of TNBC patients. We defined various ICI patterns by unsupervised clustering and constructed the ICI scores using the principal component analysis (PCA). We observed patients with different clustering patterns had distinct ICI profiles and different signatures of differentially expressed genes. Patients with a high ICI score tended to have an increased PD-L1 expression and improved outcomes, and these patients were associated with decreased tumor mutational burden (TMB). Interestingly, it was showed that patients with high TMB exhibited an ameliorated overall survival (OS) than patients with low TMB. Furthermore, TMB scores only affected the prognosis of TNBC patients in the low-ICI score group but not in the high group. Finally, we identified a new immune-related lncRNA (irlncRNA) signature and established a risk model for the TNBC prognosis prediction. In addition, the high-risk group was related to poor prognosis, a high infiltration level of plasma B cells, monocytes, M2 macrophages, and neutrophils and a low PD-L1 expression. Therefore, the characterization and systematic evaluation of ICI patterns might potentially predict the prognosis and immunotherapy response in TNBC patients.